3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia
53
Lymphoma
51
Melanoma
44
Breast Neoplasms
37
Lymphoma, Follicular
36
Leukemia, Myeloid, Acute
33
Leukemia, Lymphocytic, Chronic, B-Cell
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Lymphoma, Non-Hodgkin
29
Neuroblastoma
28
Multiple Myeloma
28
Lymphoma, Large B-Cell, Diffuse
25
Prostatic Neoplasms
23
Lymphoma, Mantle-Cell
23
Myelodysplastic Syndromes
22
Lymphoma, Large-Cell, Immunoblastic
20
Neoplasms, Plasma Cell
19
Leukemia, Myeloid, Chronic-Phase
19
Hodgkin Disease
18
Carcinoma, Non-Small-Cell Lung
18
Burkitt Lymphoma
18
Ovarian Neoplasms
17
Lymphoma, B-Cell, Marginal Zone
17
Lung Neoplasms
17
Neoplasm Metastasis
16
Glioblastoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Congenital Abnormalities
15
Leukemia, Myeloid, Accelerated Phase
14
Gliosarcoma
12
Interventions
sargramostim
1
Vaccines
1
Temozolomide
1
Papillomavirus Vaccines
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tetanus
×
sargramostim
×
Clear all
NCT03927222
2024-04-08
I-ATTAC
Duke University
Phase 2
Terminated
6 enrolled
7 charts